The outline of his presentation included:
- Current guidelines for metastatic RCC
- The rational behind cytoreductive nephrectomy (CN)
- Historical evidence supporting current guidelines
- A discussion about the results from the CARMENA trial, which compared sunitinib alone nephrectomy followed by sunitinib.
Dr Bratslavsky concluded that it is important to remember that the optimal candidates for cytoreductive nephrectomy are those with good performance and minimal disease. The role of cytoreductive nephrectomy is even less clear now in the era of immunotherapy.